Dextroamphetamine Saccharate, 5 mg recall — Lannett Company Inc. (Class II)

Lannett Company Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Dextroamphetamine Saccharate, 5 mg — a Class II recall, initiated 2026-06-26 and posted to the FDA enforcement report on 2026-07-08, under recall number D-0660-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.”. From the product description, the form is extended-release capsules, the strength given is 5 mg, the package is described as 100 capsules and it is marked Rx only. 1 National Drug Code number is printed in the record: 0527-0790-37. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in IN, United States. It is the only recall number the FDA has filed under event ID 99319. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0660-2026
FDA event ID 99319
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Lannett Company Inc.
Recall initiated 2026-06-26
Reported by FDA 2026-07-08
Report lag 12 days from initiation to report
Distribution US Nationwide. — Nationwide (US)
Firm location on record IN, United States
Product description (source) Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules, 5 mg, Rx Only, 100 capsules, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136, NDC: 0527-0790-37.

Reason reported by FDA

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

14 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

6 identifying values matched by exact pattern in the 28-word product description above; each is a literal substring of it.

Product named Dextroamphetamine Saccharate
Form Extended-Release Capsules
Strength 5 mg
Package 100 capsules
NDC 0527-0790-37
Marketing category Rx only
Distributed by Lannett Company, Inc.

Other indexed recalls from Lannett Company Inc.

3 indexed records name Lannett Company Inc. as the recalling firm, across 3 FDA events, reported 2026-05-27 to 2026-07-08. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Niacin Extended-release Tablets, 1,000 mgD-0584-2026Class II1,000 mg · Extended-Release Tablets2026-06-10
Primidone Tablets USP, 250mgD-0533-2026Class III250mg · Tablets2026-05-27

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
BD ChloraPrep Hi-Lite Orange, 2%D-0643-2026Carefusion 213, LLCClass II2026-07-08
BD PurPrep, 8.3%D-0644-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Clear, 2%D-0645-2026Carefusion 213, LLCClass II2026-07-08
ChloraPrep FREPP, 2%D-0646-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Hi-Lite Orange, 2%D-0647-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Hi-Lite Orange, 2%D-0648-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Scrub Teal, 2%D-0649-2026Carefusion 213, LLCClass II2026-07-08
BD ChloraPrep Scrub Teal, 2%D-0650-2026Carefusion 213, LLCClass II2026-07-08

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 6 nearest to 2026-07-08 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
BD ChloraPrep CLear, 2%D-0651-2026Carefusion 213, LLC2% · Solution2026-07-08
BD ChloraPrep CLear, 2%D-0652-2026Carefusion 213, LLC2% · Solution2026-07-08
IMULDOSA, 130 mg/26 mLD-0653-2026Accord Biopharma Inc130 mg/26 mL · Injection2026-07-08
prednisoLONE Acetate Ophthalmic Suspension, 1%D-0655-2026Lupin Pharmaceuticals Inc.1% · Ophthalmic Suspension2026-07-08
Levothyroxine Sodium Tablets, 300 mcgD-0656-2026Accord Healthcare, Inc.300 mcg · Tablets2026-07-08
Synjardy XR Tablets, 1000 mgD-0657-2026Boehringer Ingelheim Pharmaceuticals, Inc.1000 mg · Extended-Release Tablets2026-07-08

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 0527-0790-37 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Lannett Company Inc. (6 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0660-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0660-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-08
Ingested
2026-08-22
Record hash
f2da82125db9b148

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.